Erick Brown, DO
Psychiatry · Leawood, KSNPI 1689834335
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 528 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 528 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$497
- Lundbeck LLC$490
- Neurocrine Biosciences, Inc.$435
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$434
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $1,469 |
| Otsuka America Pharmaceutical, Inc. | 71 | $1,026 |
| Johnson & Johnson | 30 | $497 |
| Lundbeck LLC | 28 | $490 |
| Neurocrine Biosciences, Inc. | 23 | $435 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $434 |
| Axsome Therapeutics, Inc. | 20 | $423 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $396 |
| Corium, LLC | 23 | $350 |
| Vanda Pharmaceuticals Inc. | 12 | $312 |
| Avanir Pharmaceuticals, Inc. | 27 | $225 |
| Teva Pharmaceuticals USA, Inc. | 11 | $193 |
| Neos Therapeutics, LP | 19 | $187 |
| Supernus Pharmaceuticals, Inc. | 10 | $180 |
| Ironshore Pharmaceuticals Inc. | 6 | $155 |
| Tris Pharma Inc | 8 | $133 |
| Sunovion Pharmaceuticals Inc. | 41 | $125 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Collegium Pharmaceutical, Inc. | 4 | $74 |
| Acadia Pharmaceuticals Inc | 4 | $74 |
| Merck | 5 | $71 |
| Shire North American Group Inc | 5 | $65 |
| Alkermes, Inc. | 3 | $64 |
| Biogen | 3 | $58 |
| Arbor Pharmaceuticals, Inc. | 4 | $49 |
| Almatica Pharma LLC | 3 | $48 |
| Bausch Health US, LLC | 2 | $41 |
| Alfasigma USA, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
How this compares
$7,733 in reported general payments places this provider in the 85th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $82,667 |
| SpravatoEsketamine Hcl | 49 | $58,927 |
| VraylarCariprazine Hcl | 15 | $23,201 |
| Aripiprazole | 191 | $17,791 |
| TrintellixVortioxetine Hydrobromide | 21 | $14,329 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,353 |
| BelsomraSuvorexant | 26 | $11,020 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,233 |
| Ambien CrZolpidem Tartrate | 13 | $7,967 |
| Duloxetine Hcl | 301 | $7,592 |
| Bupropion XlBupropion Hcl | 298 | $7,216 |
| Lurasidone Hcl | 43 | $6,868 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 154 | $6,735 |
| Trazodone Hcl | 483 | $6,028 |
| ZoloftSertraline Hcl | 12 | $5,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $435 | $82,66711 claims |
| Johnson & JohnsonSpravato | $497 | $58,92749 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $396 | $23,56245 claims |
| AbbVieVraylar | $1,469 | $23,20115 claims |
| Axsome Therapeutics, Inc.Auvelity | $423 | $13,35312 claims |
| MerckBelsomra | $71 | $11,02026 claims |
| Shire North American Group IncMydayis | $65 | $5,54912 claims |
| Almatica Pharma LLCSertraline Hcl | $48 | $1,292190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Leawood
- Kevin MaysLeawood$548K
- Sonni ElliottLeawood$22K
- Andrew SegravesLeawood$19K
- Michael EversonLeawood$19K
- Steven SegravesLeawood$13K
- Lolitta AznaurovaLeawood$11K
- Christopher van HornLeawood$10K
- Sherman ColeLeawood$8K
- Wade HachinskyLeawood$7K
- Salma VelazquezLeawood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.